Quantitative PET/CT could improve prostate cancer treatment

June 26, 2013

Men suffering from prostate cancer have a very high chance of developing bone metastases, making it imperative to track and effectively treat local and distant tumors, especially in castrate-resistant cases. Metabolic imaging with FDG PET could provide a biomarker for predicting patients’ survival, which has been found to be a beneficial indicator in the prognosis of patients with this highly variable disease, according to a study published June 19 in the Journal of Nuclear Medicine .

Hossein Jadvar, MD, PhD, vice chair of radiology at Keck School of Medicine of USC, University of Southern California in Los Angeles, and colleagues evaluated the effectiveness of quantitative FDG PET/CT, and specifically parameters of tracer uptake for assessing overall survival of castrate-resistant metastatic prostate cancer.